Treatment of Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma with Two Ifosfamide-Based Regimens, IMVP and ICE

被引：3
|
作者：
Aurer, I. [1 ]
Mitrovic, Z. [1 ]
Nemet, D. [1 ]
Radman, I. [1 ]
Sertic, D. [1 ]
Serventi-Seiwerth, R. [1 ]
Stern-Padovan, R. [2 ]
Santek, F. [3 ]
Nola, M. [4 ]
Mrsic, M. [1 ]
Labar, B. [1 ]
机构：
[1] Univ Hosp Ctr Rebro, Dept Internal Med, Div Hematol, Zagreb 10000, Croatia
[2] Univ Hosp Ctr Rebro, Dept Radiol, Zagreb 10000, Croatia
[3] Univ Hosp Ctr Rebro, Dept Oncol, Zagreb 10000, Croatia
[4] Univ Hosp Ctr Rebro, Dept Pathol, Zagreb 10000, Croatia
来源：
JOURNAL OF CHEMOTHERAPY | 2008年 / 20卷 / 05期
关键词：
Lymphoma non-Hodgkin; lymphoma B-cell; lymphoma diffuse; lymphoma large-cell; lymphoma T-cell; ifosfamide; methotrexate; etoposide; carboplatinum;
D O I：
10.1179/joc.2008.20.5.640
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We report the outcomes of 45 patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) treated with a combination of ifosfamide, carboplatinum and etoposide (ICE) and 28 patients treated with a combination of ifosfamide, methotrexate and etoposide (IMVP) during two 5-year periods. The response rate (RR) to ICE was 47%, 2-year overall survival (OS) 31% and 2-year event-free survival (EFS) 22%. These results were similar to those obtained with IMVP (RR 39%, 2-year OS 23%, 2-year EFS 13%; p=0.355 for RR, 0.275 for OS, 0.668 for EFS). Higher IPI scores and refractoriness to treatment were negative prognostic factors, immunophenotype (B vs. T) had no influence on prognosis. Changing from IMVP to ICE does not substantially improve the outcome of patients with relapsed or refractory aggressive NHL. Patients with relapsed/refractory aggressive B-NHL do not have a superior outcome in comparison to those with T-NHL if treated with chemotherapy alone.
引用
收藏
页码：640 / 644
页数：5
相关论文
共 50 条
  • [1] Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: Retrospective study
    Aurer, I
    Durakovic, N
    Radman, I
    Nemet, D
    Zupancic-Salek, S
    Kovacevic-Metelko, J
    Bogdanic, V
    Sertic, D
    Mrsic, M
    Mikulic, M
    Labar, B
    CROATIAN MEDICAL JOURNAL, 2002, 43 (05) : 550 - 554
  • [2] Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma
    Prichard, Mark
    Harris, Thomas
    Williams, Michael E.
    Densmore, John J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (06) : 983 - 995
  • [3] Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma
    Zelenetz, AD
    Hamlin, P
    Kewalramani, T
    Yahalom, J
    Nimer, S
    Moskowitz, CH
    ANNALS OF ONCOLOGY, 2003, 14 : 5 - 10
  • [4] PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
    Roschewski, Mark
    Izumi, Raquel
    Hamdy, Ahmed
    Patel, Manish R.
    Arkenau, Hendrik-Tobias
    de Vos, Sven
    Reagan, Patrick M.
    Zinzani, Pier Luigi
    Davies, Andrew
    Pagel, John M.
    Vose, Julie M.
    Bitman, Bojena
    Brock, Graham
    Clark, Edwin
    Frigault, Melanie M.
    Ware, Joseph
    Yang, Buyue
    Wilson, Wyndham
    Staudt, Louis
    Flinn, Ian W.
    BLOOD, 2019, 134
  • [5] Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma
    Stamatoullas, A
    Fruchart, C
    Bastit, D
    Boulet, D
    Monconduit, M
    Piguet, H
    Tilly, H
    CANCER, 1996, 77 (11) : 2302 - 2307
  • [6] Changing from a first to second generation ifosfamide-based chemotherapy regimen (from IMVP to ICE) does not improve outcome of patients with relapsed or refractory aggressive
    Aurer, I.
    Mitrovic, Z.
    Nemet, D.
    Radman, I.
    Sertic, D.
    Serventi-Seiwerth, R.
    Stem-Padovan, R.
    Santek, F.
    Nola, M.
    Mrsic, M.
    Labar, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 360 - 360
  • [7] Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma
    Blum, Kristie A.
    Hamadani, Mehdi
    Phillips, Gary S.
    Lozanski, Gerard
    Johnson, Amy J.
    Lucas, David M.
    Smith, Lisa L.
    Baiocchi, Robert
    Lin, Thomas S.
    Porcu, Pierluigi
    Devine, Steven M.
    Byrd, John C.
    LEUKEMIA & LYMPHOMA, 2009, 50 (07) : 1232 - 1234
  • [8] Gemcitabine as single agent in the treatment of relapsed or refractory aggressive non-Hodgkin lymphoma (NHL)
    Welt, A
    Fossa, A
    Blatter, J
    Buksmaui, S
    Seeber, S
    Nowrousian, MR
    ANNALS OF ONCOLOGY, 1998, 9 : 168 - 168
  • [9] Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma
    Fosså, A
    Santoro, A
    Hiddemann, W
    Truemper, L
    Niederle, N
    Buksmaui, S
    Bonadonna, G
    Seeber, S
    Nowrousian, MR
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) : 3786 - 3792
  • [10] Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma
    Blum, Kristie A.
    Hamadani, Mehdi
    Phillips, Gary S.
    Lozanski, Gerard
    Johnson, Amy J.
    Lucas, David M.
    Smith, Lisa L.
    Baiocchi, Robert
    Lin, Thomas S.
    Porcu, Pierluigi
    Devine, Steven M.
    Byrd, John C.
    LEUKEMIA & LYMPHOMA, 2009, 50 (03) : 349 - 356
12345